Stay updated on Indoximod Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Indoximod Combo in Melanoma Clinical Trial page.

Latest updates to the Indoximod Combo in Melanoma Clinical Trial page
- Check4 days agoChange DetectedAn NIH-wide announcement about website terminology appears above the 403 error page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe ClinicalTrials.gov page continues to display a 403 Forbidden error, with the footer showing revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check32 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the detailed trial information with a generic error screen. This blocks access to the trial’s details, contacts, locations, and documents until the issue is resolved.SummaryDifference18%

- Check39 days agoChange DetectedA site-wide revision badge was added (v3.7.0). Melanoma-related glossary entries (Melanoma, related topics:, MedlinePlus Genetics) and an earlier revision note (Revision: v3.6.6) were removed.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page's related topics metadata was updated to include Melanoma and MedlinePlus Genetics. The revision version was updated from v3.6.5 to v3.6.6.SummaryDifference0.2%

- Check60 days agoChange DetectedRemoved Melanoma, the related topics header, and MedlinePlus Genetics from the page's related topics section. This reduces the visible topical references that help categorize and surface the study.SummaryDifference0.2%

Stay in the know with updates to Indoximod Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Indoximod Combo in Melanoma Clinical Trial page.